ITGB2 and neoplasm: After the combined treatment, it was found that two EZH2 target genes were upregulated, namely the tumor suppressor gene RASSF5 (ras association domain family member 5) and ITGB2 (integrin subunit Beta 2), which is associated with anti-tumor immunity [111,112].